NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01109264,Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia,https://clinicaltrials.gov/study/NCT01109264,,COMPLETED,To compare the clinical efficacy and safety of bendamustine hydrochloride versus chlorambucil for initial treatment of chronic lymphocytic leukemia,NO,Chronic Lymphocytic Leukemia,DRUG: Bendamustine hydrochloride injection|DRUG: Chlorambucil,"Objective Response Rate (ORR), after 3 cycles and 6 cycles","Progression-free Survival (PFS), December 2013|Duration of Remission (DR), December 2013|Overall Survival (OS), December 2013|The incidence and severity of adverse events, Up to 2 years after enrollment",,"Jiangsu Simcere Pharmaceutical Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE2,147,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,SIM-79-001,2010-03,2013-06,2013-08,2010-04-23,,2013-08-23,"Ruijin Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Shanghai, China",
